Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma

Munechika Enjoji, Shusuke Morizono, Kazuhiro Kotoh, Motoyuki Kohjima, Yuzuru Miyagi, Tsuyoshi Yoshimoto, Makoto Nakamuta

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Aim: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). Methods: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNα/5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNα (3×106 units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4th wk. The effect of combination chemotherapy was evaluated in each patient after every cycle based on the reduction of tumor volume. Results: After the 1st cycle of therapy, 16 patients showed a partial response (PR, 57.1%) but none showed a complete response (CR, 0%). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5%. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. Conclusion: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size after the first cycle of IFNα/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored.

元の言語英語
ページ(範囲)5685-5687
ページ数3
ジャーナルWorld Journal of Gastroenterology
11
発行部数36
DOI
出版物ステータス出版済み - 9 28 2005

Fingerprint

Combination Drug Therapy
Fluorouracil
Interferons
Hepatocellular Carcinoma
Antineoplastic Combined Chemotherapy Protocols
Therapeutics
Hepatic Artery
Tumor Burden
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma. / Enjoji, Munechika; Morizono, Shusuke; Kotoh, Kazuhiro; Kohjima, Motoyuki; Miyagi, Yuzuru; Yoshimoto, Tsuyoshi; Nakamuta, Makoto.

:: World Journal of Gastroenterology, 巻 11, 番号 36, 28.09.2005, p. 5685-5687.

研究成果: ジャーナルへの寄稿記事

Enjoji, Munechika ; Morizono, Shusuke ; Kotoh, Kazuhiro ; Kohjima, Motoyuki ; Miyagi, Yuzuru ; Yoshimoto, Tsuyoshi ; Nakamuta, Makoto. / Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma. :: World Journal of Gastroenterology. 2005 ; 巻 11, 番号 36. pp. 5685-5687.
@article{30a0c1c5b4d542c9a1f41e0c6b101260,
title = "Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma",
abstract = "Aim: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). Methods: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNα/5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNα (3×106 units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4th wk. The effect of combination chemotherapy was evaluated in each patient after every cycle based on the reduction of tumor volume. Results: After the 1st cycle of therapy, 16 patients showed a partial response (PR, 57.1{\%}) but none showed a complete response (CR, 0{\%}). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5{\%}. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. Conclusion: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size after the first cycle of IFNα/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored.",
author = "Munechika Enjoji and Shusuke Morizono and Kazuhiro Kotoh and Motoyuki Kohjima and Yuzuru Miyagi and Tsuyoshi Yoshimoto and Makoto Nakamuta",
year = "2005",
month = "9",
day = "28",
doi = "10.3748/wjg.v11.i36.5685",
language = "English",
volume = "11",
pages = "5685--5687",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

TY - JOUR

T1 - Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma

AU - Enjoji, Munechika

AU - Morizono, Shusuke

AU - Kotoh, Kazuhiro

AU - Kohjima, Motoyuki

AU - Miyagi, Yuzuru

AU - Yoshimoto, Tsuyoshi

AU - Nakamuta, Makoto

PY - 2005/9/28

Y1 - 2005/9/28

N2 - Aim: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). Methods: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNα/5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNα (3×106 units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4th wk. The effect of combination chemotherapy was evaluated in each patient after every cycle based on the reduction of tumor volume. Results: After the 1st cycle of therapy, 16 patients showed a partial response (PR, 57.1%) but none showed a complete response (CR, 0%). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5%. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. Conclusion: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size after the first cycle of IFNα/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored.

AB - Aim: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). Methods: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNα/5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNα (3×106 units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4th wk. The effect of combination chemotherapy was evaluated in each patient after every cycle based on the reduction of tumor volume. Results: After the 1st cycle of therapy, 16 patients showed a partial response (PR, 57.1%) but none showed a complete response (CR, 0%). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5%. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. Conclusion: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size after the first cycle of IFNα/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored.

UR - http://www.scopus.com/inward/record.url?scp=28044457714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044457714&partnerID=8YFLogxK

U2 - 10.3748/wjg.v11.i36.5685

DO - 10.3748/wjg.v11.i36.5685

M3 - Article

VL - 11

SP - 5685

EP - 5687

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -